Tradestie Institutional Equity Comparison Engine

UTHR vs TAK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TAK Overall Edge

TAK Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Valuation, Momentum & Technical while UTHR counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, UTHR trades at 18.8x Forward P/E with 39.4% operating margin (+4.1% YoY revenue) versus TAK at 12.7x Forward P/E and 16.6% operating margin (+6.7% YoY). In options structure, UTHR sits in SURGE (6th %ile IV; Dealer Gamma Walls on Pro) against TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TAK
UTHR 18.8x vs TAK 12.7x Fwd P/E
Growth & Margin Winner UTHR
Op Margin 39.4% vs 16.6% ยท YoY +4.1% vs +6.7%
Momentum & Technical Winner TAK
1Y +26.4% vs +51.8% ยท 52W Pos 81% vs 97%
Options & Structure Winner UTHR
SURGE (6th %ile IV) vs UNCLASSIFIED (5th %ile IV)
UTHR NASDAQ
United Therapeutics Corp
Pharmaceutical Preparations
$584.19
-1.18% 1D
Market Cap $25.3B
1M Return +9.58%
1Y Return +26.37%
Forward P/E 18.8x
Unified AI Score
44.8 / 100 HOLD
Tech 36.0 Fund 45.0 Flow 68.0 Mom 31.1
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: UTHR +26.37% TAK +51.79% Spread: +25.42 pp (TAK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
UTHR TTM Op. Margin: 39.4% TAK TTM Op. Margin: 16.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UTHR vs TAK. Trailing 12-month operating profitability (UTHR 39.4% vs TAK 16.6%) and valuation multiples (UTHR 18.8x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: UTHR (4) vs TAK (6)
Institutional Metric UTHR TAK Criterion Row Winner
Market Capitalization Scale $25.3B $67.5B Larger Scale TAK
Trailing P/E Ratio Valuation 22.4x N/M Lower Multiple UTHR
Forward P/E Ratio Valuation 18.8x 12.7x Lower Multiple TAK
Revenue Growth (YoY) Growth +4.1% +6.7% Higher Growth TAK
Operating Margin (TTM) Profitability 39.4% 16.6% Higher Margin UTHR
Net Profit Margin Profitability 38.6% 0.9% Higher Margin UTHR
Return on Equity (ROE) Capital Efficiency 19.1% 0.6% Higher ROE UTHR
52-Week Range Position Momentum 81% ($456โ€“$614) 97% ($14โ€“$22) Stronger Trend TAK
Beta / 30D Volatility Risk Regime 0.34ฮฒ ยท 34% Vol -0.02ฮฒ ยท 22% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 44.8 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full UTHR vs TAK Buy Guide
UTHR SURGE
8d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live UTHR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither UTHR nor TAK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.